Clinical 1: Amarasate® Mode of Action

The Amarasate® extract was tested in a human clinical trial with 20 healthy men. The study involved a randomized, double-blind, placebo-controlled cross-over study (a study where neither participants nor researchers knew what capsules were taken, and each participant took each of the capsules one week apart). Participants’ food intake was measured after taking the Amarasate® extract delivered in a patented capsule that opened in the stomach or in the duodenum, or a placebo. The study showed that when Amarasate® was delivered to the duodenum, participants ate, on average, 944kJ (226 calories) less than with placebo over 3.5 hours.

This equates to an 18% drop in overall energy intake over that period.

Figure1: The effect of treatment on ad libitum energy intake (kJ) at the outcome lunch (12:00 h), snack (14:00 h), and the combined intake (Total intake). Treatments comprised either a vehicle control (Placebo) or a formulated hops extract, Calocurb. A significant effect of treatment was observed for both the snack (P = 0.027) and for total intake (P = 0.006). Values are means ± SEMs (n = 19). ∗P < 0.05.

Figure 2: Stimulation of TAS2R receptors on enteroendocrine cells to release gastric hormones (GLP-1 and CCK) at six times baseline levels, twice the normal post-prandial release

Reference

Walker, E. G., Lo, K. R., Pahl, M. C., Shin, H. S., Lang, C., Wohlers, M. W., Poppitt, S. D., Sutton, K. H., & Ingram, J. R. (2022). An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. The American journal of clinical nutrition, 115(3), 925–940. https://doi.org/10.1093/ajcn/nqab418